|
Colorectal Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
The combination of two mRNAs, KRTAP5-4 and MAGEA3, and one lncRNA, BCAR4, could be potential candidates to detect colorectal cancer.
|
27197301 |
2016 |
|
Malignant neoplasm of colon and/or rectum
|
0.020 |
Biomarker
|
disease |
BEFREE |
The combination of two mRNAs, KRTAP5-4 and MAGEA3, and one lncRNA, BCAR4, could be potential candidates to detect colorectal cancer.
|
27197301 |
2016 |
|
Secondary malignant neoplasm of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
Consistently, knockdown of BCAR4 inhibits osteosarcoma tumorigenesis and lung metastasis in vivo.
|
27460090 |
2016 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
BCAR4 (Breast Cancer Anti-Estrogen Resistance 4) is a long noncoding RNA that was identified as an oncogene in breast cancer.
|
29190958 |
2017 |
|
Malignant neoplasm of breast
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The expression levels of BCAR4 and YAP are positively correlated in tissue samples from breast cancer patients, where high expression of both BCAR4 and YAP is associated with poor patient survival outcome.
|
28963395 |
2017 |
|
Malignant neoplasm of breast
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
BCAR4 is reported to be highly expressed in breast cancer and promotes cell proliferation.
|
28537678 |
2017 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
LncRNA breast cancer anti-estrogen resistance 4 (BCAR4) has been identified as an oncogenic lncRNA involved in the progression of breast cancer and osteosarcoma.
|
28077810 |
2017 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
BCAR4 (Breast Cancer Anti-Estrogen Resistance 4) is a long noncoding RNA that was identified as an oncogene in breast cancer.
|
29190958 |
2017 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
BCAR4 is reported to be highly expressed in breast cancer and promotes cell proliferation.
|
28537678 |
2017 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
LncRNA breast cancer anti-estrogen resistance 4 (BCAR4) has been identified as an oncogenic lncRNA involved in the progression of breast cancer and osteosarcoma.
|
28077810 |
2017 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The expression levels of BCAR4 and YAP are positively correlated in tissue samples from breast cancer patients, where high expression of both BCAR4 and YAP is associated with poor patient survival outcome.
|
28963395 |
2017 |
|
Neoplasm Metastasis
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
In addition, the BCAR4 expression was associated with the lymph node metastasis, distant metastasis and clinical stage, but not with the age, sex, tumor size, histological grade, and histological type.
|
28077810 |
2017 |
|
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
BCAR4 was higher in NSCLC tissues than that in cancer-adjacent tissues and was positively correlated with tumor size, clinical stage, and distant metastasis, suggesting that BCAR4 can be used as an independent predictor of prognosis.
|
28537678 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Besides, BCAR4 knockdown decreased tumor growth <i>in vivo</i>.
|
29190958 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The tumor volume was monitored to evaluate the effect of BCAR4 on chondrosarcoma cell tumorigenicity.
|
28399646 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
BCAR4 was higher in NSCLC tissues than that in cancer-adjacent tissues and was positively correlated with tumor size, clinical stage, and distant metastasis, suggesting that BCAR4 can be used as an independent predictor of prognosis.
|
28537678 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We also found that the expression of BCAR4 was significantly related to the size of the tumor, clinical classification and the survival time.
|
29028095 |
2017 |
|
Testicular Germ Cell Tumor
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Meta-analysis of five genome-wide association studies identifies multiple new loci associated with testicular germ cell tumor.
|
28604732 |
2017 |
|
Testicular Germ Cell Tumor
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Identification of 19 new risk loci and potential regulatory mechanisms influencing susceptibility to testicular germ cell tumor.
|
28604728 |
2017 |
|
Osteosarcoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
In this study, we performed a meta-analysis on four lncRNAs (TUG1, UCA1, BCAR4, and HULC) to systematically evaluate their prognostic value in osteosarcoma.
|
29184421 |
2017 |
|
Osteosarcoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
LncRNA breast cancer anti-estrogen resistance 4 (BCAR4) has been identified as an oncogenic lncRNA involved in the progression of breast cancer and osteosarcoma.
|
28077810 |
2017 |
|
Osteosarcoma of bone
|
0.050 |
Biomarker
|
disease |
BEFREE |
In this study, we performed a meta-analysis on four lncRNAs (TUG1, UCA1, BCAR4, and HULC) to systematically evaluate their prognostic value in osteosarcoma.
|
29184421 |
2017 |
|
Osteosarcoma of bone
|
0.050 |
Biomarker
|
disease |
BEFREE |
LncRNA breast cancer anti-estrogen resistance 4 (BCAR4) has been identified as an oncogenic lncRNA involved in the progression of breast cancer and osteosarcoma.
|
28077810 |
2017 |
|
Childhood Osteosarcoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
In this study, we performed a meta-analysis on four lncRNAs (TUG1, UCA1, BCAR4, and HULC) to systematically evaluate their prognostic value in osteosarcoma.
|
29184421 |
2017 |
|
Childhood Osteosarcoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
LncRNA breast cancer anti-estrogen resistance 4 (BCAR4) has been identified as an oncogenic lncRNA involved in the progression of breast cancer and osteosarcoma.
|
28077810 |
2017 |